Content area
Full text
Drs. Elliott and Chan report no financial relationships relevant to this field of study.
The FDA has approved a second interleukin-23 (IL-23) inhibitor for the treatment of adults with moderate-to-severe plaque psoriasis who are eligible for systemic therapy or phototherapy. Tildrakizumab-asmn is a humanized IgG1/k antibody that binds to the p19 subunit of IL-23, similar to guselkumab, a human IgG1/k antibody. Tildrakizumab-asmn is marketed as Ilumya.
INDICATIONS
Tildrakizumab-asmn is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.1
DOSAGE
The recommended dose is 100 mg given subcutaneously at weeks 0, 4, and every 12 weeks thereafter.1 Ilumya is available as 100 mg/mL single-dose prefilled syringes.
POTENTIAL ADVANTAGES
The mean elimination half-life of tildrakizumab-asmn is approximately 23 days, which allows dosing every 12 weeks.
In contrast, guselkumab has a mean half-life of 15-18 days and is dosed every eight weeks.
POTENTIAL DISADVANTAGES
The most frequently reported adverse reactions were infections (14%), injection site reactions (3%), and diarrhea (2%).1 Corresponding placebo rates were 12%, 2%, and 1%, respectively. Approximately 2.5% of subjects developed neutralizing antibodies. Cases of angioedema and urticaria have been reported.
COMMENTS
The...